Levosimendan Pretreatment for Weaning Patients From Cardio-Pulmonary Bypass

The study evaluates the efficacy of intravenous levosimendan treatment started during a coronary artery bypass operation to wean patients from a heart lung machine.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Coronary Heart Disease Cardiovascular Diseases Coronary Disease Heart Diseases Myocardial Ischemia Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Helsinki University Central Hospital, Helsinki, Finland

About this study

Levosimendan or placebo infusion is started at the time of induction of anesthesia.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Three vessel coronary artery disease.
Indication for on-pump coronary artery bypass surgery.
Ejection fraction below 50%

Exclusion criteria

Indication for any cardiac valve surgery
Previous coronary artery bypass surgery

Treatment and study plan

Levosimendan

Drug

Primary outcomes

Proportion of successful primary weanings

Sponsors and collaborators

Lead sponsor

Orion Corporation, Orion Pharma

Industry

Registry information

Official study title

Impact of Levosimendan Pretreatment on Weaning From Cardiopulmonary Bypass (CPB) in Patients With Diminished Left Ventricular Function Before Coronary Artery Bypass Grafting (CABG)

Important dates

Study start: 2004
Study completion: 2006
First posted: Aug 16, 2005
Registry last updated: Feb 21, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed